| Titre : | Clinical Infectious Diseases, Vol.57, Suppl.2 - August 2013 - Prevention and management of hepatitis C virus infection among people who inject drugs: Moving the agenda forward |
| Type de document : | Bulletin : Périodique |
| Paru le : | 15/08/2013 |
| Année de publication : | 2013 |
| Langues: | Anglais |
| Discipline : | MAL (Maladies infectieuses / Infectious diseases) |
| Mots-clés : |
Thésaurus TOXIBASE HEPATITE |
| Domaine : | Drogues illicites / Illicit drugs |
| Sous-type de document : | N° spécial de revue / Special issue of a journal |
Dépouillements
Ajouter le résultat dans votre panier
Article : Périodique
J. GREBELY ;
P. BRUGGMANN ;
M. BACKMUND ;
G. J. DORE
|
The majority of hepatitis C virus (HCV) occurs among people who inject drugs (PWID), and the burden of HCV-related liver disease is still increasing. HCV treatment is safe and effective among PWID, and international guidelines encourage HCV trea[...]
Article : Périodique
K. PAGE ;
M. D. MORRIS ;
J. A. HAHN ;
L. MAHER ;
M. PRINS
|
The hepatitis C virus (HCV) virus epidemic is ongoing in the United States and globally. Incidence rates remain high, especially in young adult injection drug users. New outbreaks of HCV in the United States among young adults, in predominantly [...]
Article : Périodique
BACKGROUND: Interventions such as opiate substitution therapy (OST) and high-coverage needle and syringe programs (HCNSP) cannot substantially reduce hepatitis C virus (HCV) prevalence among people who inject drugs (PWID). HCV antiviral treatmen[...]
Article : Périodique
One of the major obstacles to hepatitis C virus (HCV) care in people who inject drugs (PWID) is the lack of treatment settings that are suitably adapted for the needs of this vulnerable population. Nevertheless, HCV treatment has been delivered [...]
Article : Périodique
M. ALAVI ;
J. GREBELY ;
M. MICALLEF ;
A. J. DUNLOP ;
A. C. BALCOMB ;
C. A. DAY ;
C. TRELOAR ;
N. BATH ;
P. S. HABER ;
G. J. DORE
|
BACKGROUND: Access to hepatitis C virus (HCV) treatment remains extremely limited among people who inject drugs (PWID). HCV assessment and treatment was evaluated through an innovative model for the provision of HCV care among PWID with chronic [...]
Article : Périodique
E. ASPINALL ;
S. CORSON ;
J. S. DOYLE ;
J. GREBELY ;
S. J. HUTCHINSON ;
G. J. DORE ;
D. J. GOLDBERG ;
M. E. HELLARD
|
BACKGROUND: Although guidelines recommend that people who inject drugs (PWID) should not be excluded from hepatitis C (HCV) treatment, some services remain reluctant to treat PWID. The aim of this review was to investigate sustained virologic re[...]
Article : Périodique
B. P. GRADY ;
J. SCHINKEL ;
X. V. THOMAS ;
O. DALGARD
|
Most new cases of hepatitis C virus (HCV) infections in the developed world are associated with injection drug use. However, treatment for people who inject drugs (PWID) is controversial, as successful treatment risks being followed by new infec[...]
Article : Périodique
Boceprevir and telaprevir are inhibitors and substrates of the cytochrome P450 3A4 family. With the use of these HCV protease inhibitors as part of standard therapy for chronic hepatitis C genotype 1 infection, drug-drug interactions with multip[...]
Article : Périodique
G. ROBAEYS ;
J. GREBELY ;
S. MAUSS ;
P. BRUGGMANN ;
J. MOUSSALLI ;
A. DE GOTTARDI ;
T. SWAN ;
A. ARAIN ;
A. KAUTZ ;
H. STÖVER ;
H. WEDEMEYER ;
M. SCHAEFER ;
L. TAYLOR ;
M. BACKMUND ;
O. DALGARD ;
M. PRINS ;
G. J. DORE
|
In the developed world, the majority of new and existing hepatitis C virus (HCV) infections occur among people who inject drugs (PWID). The burden of HCV-related liver disease in this group is increasing, but treatment uptake among PWID remains [...]
Article : Périodique
People who inject drugs (PWID) are the group most affected by HCV; however, treatment uptake has been low. Engagement between PWID and healthcare workers has been characterized by mistrust and discrimination. Peer support for HCV is one way to o[...]
Exemplaires
| Disponibilité |
|---|
| aucun exemplaire |
Accueil
